Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
4 hedge funds and large institutions have $2.99M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more capital invested
Capital invested by funds: $2.98M → $2.99M (+$9.49K)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$34.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$101 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EC
1
EcoR1 Capital
San Francisco,
California
| $2.03M | – | – | – |
|
|
SIA
2
SkyView Investment Advisors
Shrewsbury,
New Jersey
| $728K | – | – | – |
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $222K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $7K | -$101 | -10 | -2% |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$34.8K | -3,483 | Closed |
|
EUCR Hedge Fund Activity: Q1 2023 in Review
4 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q1 2023, worth a combined $2.99M — up 0.32% from $2.98M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of EUCR and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $34.8K sold.
- 4 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q1 2023, down from 5 in Q4 2022.
- Funds reported $2.99M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q1 2023, up 0.32% quarter-over-quarter.
- 0 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q1 2023 was UBS Group, an estimated $34.8K sold.
Based on aggregated 13F filings for Q1 2023.